Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

life sciences

Roche Basel Switzerland

Roche biggest pharma R&D spender in PwC survey

Pharma giant on track to spend 21.9% of its total revenue on research this year

- PMLiVE

Ipsen’s liver cancer treatment clears phase III trial

Cabometyx on track for new liver cancer indication

- PMLiVE

Building a bright future

Mylan takes a bold approach as it doubles its pipeline through R&D and acquisitions

- PMLiVE

Effective strategic planning

The advantages of being nimble when responding to challenges

- PMLiVE

Pursuing better outcomes for people with pain

Using the patient’s voice to change how we conduct R&D

- PMLiVE

With US approval, GSK now needs rapid uptake for COPD triple

Aims to quickly launch the predicted blockbuster to revive its R&D portfolio

- PMLiVE

Ian Weatherhead joins Ipsen

Takes up corporate communications role at the French pharma firm

- PMLiVE

UK life sciences sector sets out its post-Brexit growth proposals

Review helmed by Sir John Bell outlines a wide-ranging strategy

Life at the end of the Brexit tunnel

A new proposal to maintain the UK as a benchmark of excellence in Life Sciences

Life Healthcare Communications

- PMLiVE

NICE gives green light to Ipsen’s Cabometyx

Backs the medicine’s use for patients with advanced kidney cancer

translational pharmacology medicine dose

R&D productivity still a big problem for biopharma

Firms need to include AI into their R&D processes to survive

- PMLiVE

RB and Lions Health hold air pollution innovation hack

The second annual event will focus on China

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links